Protagenic Therapeutics, Inc.\new (PTIX) SEC Filings

Protagenic Therapeutics, Inc. (PTIX) reported an insider share purchase by executive chair and principal officer, as well as director, Armen Garo H. On August 20, 2026, he purchased 16,634 shares of common stock in an open market or private transaction at $0.5898 per share, increasing his direct holdings to 53,533 shares. The filing indicates the Rule 10b5-1 trading plan checkbox was not selected.

Protagenic Therapeutics, Inc. (PTIX) reported U.S. FDA feedback on its Type B pre-IND meeting request for PT00114, its lead investigational neuropeptide for generalized anxiety disorder (GAD). FDA identified no clinical hold issues, raised no objection to the planned three-part Phase 1 design and dose-escalation approach, and viewed the proposed CMC, nonclinical, and potency/comparability packages as reasonable to support an IND submission.

PT00114 has completed single and multiple ascending dose Phase 1 studies in healthy volunteers outside the U.S., where it was reported to be well tolerated with no serious adverse events. Based on FDA feedback, Protagenic currently plans to submit an IND before the end of 2026 and is targeting first patient dosing in the first half of 2027, subject to FDA review and completion of remaining CMC, manufacturing and nonclinical work. The company notes prior filings describing substantial doubt about its ability to continue as a going concern and highlights significant capital needs and OTCQB-related risks.

Protagenic Therapeutics, Inc. (PTIX) reported that director and executive chair Armen Garo H purchased 2,700 shares of common stock on 2026-08-19 in an open-market or private transaction at $0.35 per share. Following this purchase, he directly owns 36,899 common shares. The transaction was not indicated as pursuant to a Rule 10b5-1 trading plan.

Protagenic Therapeutics, Inc. (PTIX) reported another loss-making quarter for the three months ended June 30, 2026, with a net loss of $963,616 and no revenue, compared with a net loss of $5,057,523 a year earlier. Total operating expenses were $961,247, down from $1,208,374, mainly due to lower research and development and legal costs after unwinding the Phytanix Bio merger. Other income and expense were near breakeven, versus heavy derivative and extinguishment charges in 2025.

Cash in bank declined to $565,985 from $1,509,178 at March 31, 2026, as operating activities used $944,298 in cash during the quarter and there were no investing or financing inflows. Total assets were $2.8 million, including $2.1 million of intangible assets tied to in‑process R&D and assembled workforce, and stockholders’ equity was $1.7 million.

The company discloses a working capital deficit of $362,743 at June 30, 2026 and an accumulated deficit of $4,993,245. Management states that existing cash is insufficient to fund operations for twelve months from issuance of the financial statements and that these conditions raise substantial doubt about PTIX’s ability to continue as a going concern. PTIX is exploring equity financing, partnerships for its lead program, royalty-based arrangements, and other strategic alternatives to improve liquidity.

Protagenic Therapeutics, Inc. notified the SEC that it cannot file its Quarterly Report on Form 10-Q for the period ended June 30, 2026 by the prescribed due date without unreasonable effort or expense. The company is working to complete the remaining items but does not expect to file the Form 10-Q within the five-day extension period provided by Rule 12b-25.

Protagenic Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing PT00114, a synthetic form of TCAP-1, for stress-related neuropsychiatric and mood disorders including depression, anxiety, addiction and PTSD. PT00114 has completed single- and multiple-dose Phase I testing in healthy volunteers, with a Phase 2 study planned for late 2026 and an investigational new drug resubmission anticipated in 2026 to enable U.S. Phase IIa work.

During the year ended March 31, 2026, Protagenic completed and unwound a reverse merger with Phytanix Bio, so fiscal 2026 results consolidate Phytanix only through the unwind date, limiting year-to-year comparability. The company reported net income of $1.37 million for 2026 versus a prior-year net loss, but still has an accumulated deficit of $4.03 million and no product revenue. Management states cash resources are sufficient only until the end of the third quarter of 2026, and financial statements are prepared on a going concern basis.

The business depends heavily on an exclusive license from the University of Toronto for TCAP-related intellectual property, requiring a 2.5% royalty on future net sales and a share of any sublicense fees. Operations are lean, with two full-time and one part-time employees, and extensive use of contract research and manufacturing organizations.

Protagenic Therapeutics, Inc. director and executive chair Armen Garo H reported an open-market purchase of common stock. On 2026-08-11, he purchased 2,220 shares at $0.32 per share, bringing his directly held position to 34,199 common shares. The transaction was reported as a direct ownership purchase and not under a Rule 10b5-1 trading plan.

Protagenic Therapeutics, Inc. director and executive chair Armen Garo reported purchasing 685 shares of common stock on 2026-08-06 at $0.22 per share in an open-market or private transaction. Following this transaction, his directly owned holdings total 31,979 common shares.

Protagenic Therapeutics, Inc. director and executive chair Armen Garo H purchased 5,000 shares of common stock on August 5, 2026 at $0.2588 per share in an open-market or private transaction. Following this buy, he directly holds 31,294 common shares. The transaction was not reported as made under a Rule 10b5-1 trading plan.